CAMBRIDGE, Mass. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. , (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that